Analysts Set AxoGen, Inc. (NASDAQ:AXGN) Price Target at $12.25

Shares of AxoGen, Inc. (NASDAQ:AXGN) have earned an average rating of “Buy” from the five brokerages that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $13.80.

AXGN has been the subject of a number of recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of AxoGen in a report on Thursday, June 20th. StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Friday, August 9th. JMP Securities upped their price objective on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a report on Friday, August 9th. Finally, Raymond James started coverage on AxoGen in a report on Monday, July 1st. They issued an “outperform” rating and a $13.00 target price for the company.

Institutional Investors Weigh In On AxoGen

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its position in AxoGen by 534.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 7,805 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 6,575 shares in the last quarter. Koss Olinger Consulting LLC purchased a new stake in shares of AxoGen in the 2nd quarter worth about $75,000. Lazard Asset Management LLC grew its stake in AxoGen by 30.1% in the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 2,671 shares during the last quarter. SG Americas Securities LLC increased its holdings in AxoGen by 45.9% during the 4th quarter. SG Americas Securities LLC now owns 14,823 shares of the medical equipment provider’s stock valued at $101,000 after acquiring an additional 4,666 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in AxoGen during the second quarter worth about $125,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Up 3.6 %

AXGN stock opened at $11.26 on Friday. AxoGen has a one year low of $3.45 and a one year high of $11.42. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.23 and a current ratio of 3.43. The company has a fifty day moving average of $8.21 and a 200-day moving average of $8.03. The stock has a market capitalization of $492.12 million, a PE ratio of -22.52 and a beta of 1.11.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.